Abstract
Introduction Heparin-induced thrombocytopenia is a serious immune-mediated, drug adverse effect. Research over the last 20 years has vastly expanded knowledge, awareness and management of this condition. This review includes findings mostly from primary source clinical and economic literature from this time period to synthesise a concise summary. We have highlighted key points regarding the pathophysiology, epidemiology and presentation, diagnosis and management, as well as the economic impact of heparin-induced thrombocytopenia. It is established that heparininduced thrombocytopenia is relatively uncommon overall, despite the widespread use of heparin. However, delayed recognition leads to significantly increased morbidity, mortality and disability. Treatment requires prolonged courses of expensive alternative anticoagulants. All of these impose substantial costs to patients, hospitals and society. The aim of this review was to assess the clinical and economic factors influencing heparin-induced thrombocytopenia. Conclusion Heparin-induced thrombocytopenia remains a significant clinical problem and is associated with morbidity, mortality and disability. Using heparin products can reduce (but not eliminate) the incidence of heparininduced thrombocytopenia. Properly administered treatment with factor Xa inhibitors or direct thrombin inhibitors can significantly decrease the direst complications of this condition and mitigate its economic impact.
Highlights
Heparin-induced thrombocytopenia is a serious immune-mediated, drug adverse effect
Administered treatment with factor Xa inhibitors or direct thrombin inhibitors can significantly decrease the direst complications of this condition and mitigate its economic impact
Heparin-induced thrombocytopenia (HIT) is a prothrombotic complication mediated by auto antibodies against heparin-platelet complexes
Summary
Heparin-induced thrombocytopenia is a serious immune-mediated, drug adverse effect. Research over the last 20 years has vastly expanded knowledge, awareness and management of this condition. We have highlighted key points regarding the pathophysiology, epidemiology and presentation, diagnosis and management, as well as the economic impact of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia (HIT) is a prothrombotic complication mediated by auto antibodies against heparin-platelet complexes. It causes prolonged morbidity, is fatal in 5%–10% of cases and causes lifelong disability in another 10% of cases[1]. Heparins are recommended and are widely used for prophylaxis of venous thromboembolism (VTE)[2,3] Increasing adherence with this recommendation can be expected because it is tracked as a marker of quality improvement with potential reimbursement implications, given the resource constraints in healthcare. This review draws largely on original primary source publications
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.